• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    AavantiBio Rounds Out Leadership Team with Appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer

    5/17/21 7:00:00 AM ET
    $BSX
    $BLUE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BSX alert in real time by email

    AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer. Dr. Hanrahan is the fifth senior executive to be named to the leadership team at AavantiBio in recent months. She will oversee global regulatory affairs for AavantiBio's diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical need.

    Dr. Hanrahan brings to AavantiBio nearly 15 years of experience in the biotech industry and a strong track record of achievements and leadership in global regulatory affairs and drug development. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. (NASDAQ:BLUE), where she was responsible for the global regulatory strategy for the severe genetic disease franchise. While at bluebird bio, Dr. Hanrahan worked to obtain numerous global regulatory designations from the FDA and EMA, played a critical role in the Marketing Authorization Application (MAA) submission and approval of Zynteglo, the first gene therapy product for transfusion-dependent beta-thalassemia patients, and the submission of an MAA for eli-cel, a therapy to treat cerebral adrenal leukodystrophy. She also made significant contributions toward building the company's regulatory department.

    "Jessie brings to AavantiBio robust global regulatory and development expertise along with a proven track record of contributing to the development of innovative drug products. We are thrilled to welcome her to what we believe is a best-in-class leadership team," said Bo Cumbo, President and Chief Executive Officer of AavantiBio. "With Jessie and the rest of the executive team in place, we are well-positioned to execute on our vision to leverage the transformative science of gene transfer therapy and other technologies to deliver the next generation of life-changing medicines for patients and families affected with rare, devastating diseases."

    Prior to bluebird bio, Dr. Hanrahan held positions of increasing responsibility at Genzyme Corp. (now Sanofi Genzyme) where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas, and managed regulatory activities spanning pre-investigational through New Drug Applications and post approval efforts. She played a key role in the approval of Lemtrada, an infusion therapy for relapsing forms of multiple sclerosis, in North America and Europe, and was involved in the global approval of Mozobil, a medication for patients with non-Hodgkin's lymphoma and multiple myeloma. Earlier in her career, Dr. Hanrahan worked at Boston Scientific Corporation (NYSE:BSX) as a medical writer supporting communications needs for clinical trials and registries in global markets. She received her Ph.D., M.S. and M.Ph. degrees from Yale University in Molecular, Cellular, and Developmental Biology, and holds a B.A. in Biology and History from Mount Holyoke College.

    "Regulatory science plays a vital role in advancing innovative therapies that bring hope to patients and families suffering with rare diseases," said Hanrahan, who will report to Mr. Cumbo. "I am excited to help build a strong, strategic regulatory function to support AavantiBio's important patient-centric mission."

    Since launching in October 2020 with $107 million in Series A funding from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, AavantiBio has made significant progress building out the company's strategic and operational capabilities. Over the last several months, AavantiBio has announced the appointments of Douglas J. Swirsky as Chief Financial Officer and Treasurer, Ty Howton as Chief Operating Officer and General Counsel, Christopher Wright, M.D., Ph.D., as Chief Medical Officer, and Paul Herzich as Chief Technology Officer.

    About AavantiBio, Inc.

    AavantiBio is a gene therapy company backed by a premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management, who led the company's recent $107 million Series A financing. Headquartered in Cambridge, Massachusetts, AavantiBio is advancing a diversified gene therapy pipeline in areas of high unmet medical need, including a lead program in Friedreich's Ataxia (FA), a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company benefits from strategic partnerships with the University of Florida's renowned Powell Gene Therapy Center and the MDA Care Center at UF Health where AavantiBio's co-founders and renowned gene therapy researchers Barry Byrne, M.D., Ph.D. and Manuela Corti, P.T., Ph.D. maintain their research and clinical practices. Learn more at www.aavantibio.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005274/en/

    Get the next $BSX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BSX
    $BLUE

    CompanyDatePrice TargetRatingAnalyst
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    bluebird bio Inc.
    $BLUE
    2/24/2025Underweight → Neutral
    Analyst
    bluebird bio Inc.
    $BLUE
    2/24/2025$29.00Overweight
    Analyst
    Boston Scientific Corporation
    $BSX
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    bluebird bio Inc.
    $BLUE
    11/18/2024Neutral → Underweight
    Analyst
    bluebird bio Inc.
    $BLUE
    11/15/2024Neutral → Underweight
    JP Morgan
    bluebird bio Inc.
    $BLUE
    11/15/2024$3.00 → $0.50Buy → Neutral
    BofA Securities
    More analyst ratings

    $BSX
    $BLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Boston Scientific with a new price target

      Leerink Partners initiated coverage of Boston Scientific with a rating of Outperform and set a new price target of $118.00

      6/16/25 7:46:14 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Needham with a new price target

      Needham upgraded Boston Scientific from Hold to Buy and set a new price target of $113.00

      4/16/25 9:01:10 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Bluebirdbio upgraded by Analyst

      Analyst upgraded Bluebirdbio from Underweight to Neutral

      2/24/25 7:05:14 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BSX
    $BLUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

      The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system in the treatment of drug refractory, symptomatic persistent atrial fibrillation (AF), an arrythmia in which the heart beats abnormally for at least seven days.

      7/7/25 7:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing second quarter 2025 results

      MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call. A live webcast and replay for the eve

      7/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care

    $BSX
    $BLUE
    Leadership Updates

    Live Leadership Updates

    See more
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

      Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

      4/3/25 11:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner

      BEIJING and IRVINE, Calif., Jan. 6, 2025 /PRNewswire/ -- Sherpa Healthcare Partners, a global healthcare venture capital firm focused on early and growth stage healthcare companies primarily in Asia and the United States, announced today the appointment of Raymond W. Cohen as Venture Partner. Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an Irvine, California-based global medical technology company that Cohen co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1

      1/6/25 9:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $BLUE
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific announces conference call discussing second quarter 2025 results

      MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call. A live webcast and replay for the eve

      7/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces results for first quarter 2025

      MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.56 a year ago.

      4/23/25 6:30:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing first quarter 2025 results

      MARLBOROUGH, Mass., April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 23 prior to the conference call. A live webcast and replay for the

      4/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $BLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:39:36 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:27:32 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 10:32:08 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BSX
    $BLUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      2/13/25 4:32:41 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $BLUE
    SEC Filings

    See more
    • SEC Form 11-K filed by Boston Scientific Corporation

      11-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      6/18/25 5:14:10 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SEC Form 15-12G filed by bluebird bio Inc.

      15-12G - bluebird bio, Inc. (0001293971) (Filer)

      6/12/25 6:05:15 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by bluebird bio Inc.

      EFFECT - bluebird bio, Inc. (0001293971) (Filer)

      6/4/25 12:15:02 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BSX
    $BLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 1, 2024 - FDA Roundup: March 1, 2024

      For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

      3/1/24 4:00:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

      For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

      8/17/22 2:12:27 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BSX
    $BLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP and CFO Monson Jonathan

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:43 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael exercised 50,000 shares at a strike of $26.15 and sold $5,348,315 worth of shares (50,000 units at $106.97) (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:41 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SVP, GC and Corp. Secretary Brown Vance R converted options into 4,036 shares and covered exercise/tax liability with 1,952 shares, increasing direct ownership by 7% to 33,451 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:38 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care